Estrogen and progestogen therapy in postmenopausal women

Fertility and Sterility

Volumn 81, Issue 1, 2004, Pages 231-241

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONJUGATED ESTROGEN; CYPROTERONE; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEDROXYPROGESTERONE ACETATE;

ARTHRALGIA; BEHAVIOR; BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITION; COLON CANCER; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; ENDOMETRIUM CANCER; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; FRAGILITY FRACTURE; HEADACHE; HISTOPATHOLOGY; HORMONAL THERAPY; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; MASTALGIA; MUSCLE STIFFNESS; MUSCULOSKELETAL DISEASE; OUTCOMES RESEARCH; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SENILE DEMENTIA; SIDE EFFECT; SLEEP DISORDER; STROKE; SYMPTOM; TREATMENT INDICATION; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; UTERUS BLEEDING; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS; VENOUS THROMBOEMBOLISM; WELLBEING;

EID: 0347986528     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2003.10.002     Document Type: Article

References (75)

1. Greendale G.A., Reboussin B.A., Hogan P., Barnabei V.M., Shumaker S., Johnson S., et al. Symptom relief and side effects of postmenopausal hormones results from the Postmenopausal Estrogen/Progestin Interventions trial . Obstet Gynecol. 92:1998;982-988.
2. Barnabei V.M., Grady D., Stovall D.W., Cauley J.A., Lin F., Stuenkel C.A., et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol. 100:2002;1209-1218.
3. Hays J., Ockene J.K., Brunner R.L., Kotchen J.M., Manson J.E., Patterson R.E., et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 348:2003;1839-1854.
4. MacLennan A., Lester S., Moore V. Oral estrogen replacement versus placebo for hot flushes a systematic review . Climacteric. 4:2001;58-74.
5. Wiklund I., Karlberg J., Mattson L.A. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy a double-blind placebo-controlled study . Am J Obstet Gynecol. 168:1993;824-830.
6. Ditkoff EC, Crary WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 991;78:991-5.
7. Magos A., Brewster E., Singh R., O'Dowd T., Bruncat M., Studd J.W.W. The effects of norethisterone in menopausal women on oestrogen replacement therapy a model for the premenstrual syndrome . Br J Obstet Gynaecol. 93:1986;1290-1296.
8. Rodriguez C., Calle E.E., Patel A.V., Tatham L.M., Jacobs E.J., Thun M.J. Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women. Am J Epidemiol. 153:2001;145-152.
9. Cardozo L., Bachmann G., McLish D., Fonda D., Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women second report of the Hormones and Urogenital Therapy Committee . Obstet Gynecol. 92:1998;722-727.
10. Fantl J.A., Cardozo L., McLish D.K. Hormones and Urogenital Therapy Committee. Estrogen therapy in the management of urinary incontinence in postmenopausal women first report of the Hormones and Urogenital Therapy Committee . Obstet Gynecol. 83:1994;12-18.
11. Grady D., Brown J.S., Vittinghoff E., Applegate W., Varner E., Snyder T. Postmenopausal hormones and incontinence The Heart and Estrogen/Progestin Replacement Study . Obstet Gynecol. 97:2001;116-120.
12. Speroff L., Rowan J., Symons J., Genant H., Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study). A randomized controlled study. JAMA. 276:1996;1397-1403.
13. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 280:1998;605-613.
14. Komulainen M.H., Kroger H., Tuppurainen M.T., Heikkinen A.M., Alhava E., Honkanen R., et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women a 5 year randomized trial . Maturitas. 31:1998;45-54.
15. Michaelsson K., Baron J.A., Farahmand B.Y., Johnell O., Magnusson C., Persson P.G., et al. Hormone replacement therapy and the risk of hip fracture population based case-control study. The Swedish Hip Fracture Study Group . Br Med J. 316:1998;1858-1863.
16. Ott A., Breteler M.M., van Harskamp F., Stijnen T., Hofman A. Incidence and risk of dementia the Rotterdam Study . Am J Epidemiol. 147:1998;574-580.
17. LeBlanc E.S., Janowsky J., Chan B.K.S., Nelson H.D. Hormone replacement therapy and cognition systematic review and meta-analysis . JAMA. 285:2001;1489-1499.
18. Baldereschi M., Di Carlo A., Lepore V., Bracco L., Maggi S., Grigoletto F., et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology. 50:1998;996-1002.
19. Seshadri S., Zornberg G.L., Derby L.E., Myers M.W., Jick H., Drachman D.A. Postmenopausal estrogen replacement therapy and risk of Alzheimer disease. Arch Neurol. 58:2001;435-440.
20. Slooter A.J., Bronzova J., Witteman J.C., Van Broeckhoven C., Hofman A., van Duijn C.M. Estrogen use and early onset Alzheimer's disease a population-based study . J Neurol Neurosurg Psych. 67:1999;779-781.
21. Grodstein F., Chen J., Pollen D.A., Albert M.S., Wilson R.S., Folstein M.F., et al. Postmenopausal hormone therapy and cognitive function in healthy older women. J Am Geriatr Soc. 48:2000;746-752.
22. Zandi P.P., Carlson M.C., Plassman B.L., Welsh-Bohmer K.A., Mayer L.S., Steffens D.C., et al. Hormone replacement therapy and incidence of Alzheimer's disease in older women the UCHE County Study . JAMA. 288:2002;2123-2129.
23. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., Ockene J.K., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory study a randomized controlled trial . JAMA. 289:2003;2651-2662.
24. Rapp S.R., Espeland M.A., Shumaker S.A., Henderson V.W., Brunner R.L., Manson J.E., et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women's Health Initiative Memory Study a randomized controlled trial . JAMA. 289:2003;2663-2672.
25. World Health Organization Scientific Group on Research on the Menopause in the 1990's. Research on the Menopause in the 1990's. Geneva, Switzerland: World Health Organization, 1996.
26. Grodstein F., Manson J.E., Colditz G.A., Willett W.C., Speizer F.E., Stampfer M.J. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 133:2000;933-941.
27. Herrington D.M., Reboussin D.M., Brosnihan K.B., Sharp P.C., Shumaker S.A., Snyder T.E., et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med. 343:2000;522-529.
28. PEPI Trial Writing Group. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1995;273:199-208.
29. Shlipak M.G., Simon J.A., Vittinghoff E., Lin F., Barrett-Connor E., Knopp R.H., et al. Estrogen and progestin, lipoprotein (a), and risk of recurrent coronary heart disease events after menopause. JAMA. 283:2000;1845-1852.
30. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-33.
31. Cherry N., Gilmour K., Hannaford P., Heagerty A., Khan M.A., Kitchener H., et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women a randomised placebo controlled trial . Lancet. 360:2002;2001-2008.
32. Vittinghoff E., Shlipak M.G., Varosy P.D., Furberg C.D., Ireland C.C., Khan S.S., et al. Risk factors and secondary prevention in women with heart disease the Heart and Estrogen/Progestin Replacement Study . Ann Intern Med. 138:2003;81-89.
33. Schulman S.P., Thiemann D.R., Ouyang P., Chandra N.C., Schulman D.S., Reis S.E., et al. Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina. J Am Coll Cardiol. 39:2002;231-237.
34. Collins J. Benefits and risks of hormone replacement therapy. Medicine. 29:2001;5-11.
35. Paganini-Hill A. Hormone replacement therapy and stroke risk, protection or no effect? Maturitas. 38:2001;243-261.
36. Thompson S.G., Meade T.W., Greenberg G. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. J Epidemiol Comm Health. 43:1989;173-178.
37. Grodstein F., Manson J.E., Colditz G.A., Willett W.C., Speizer F.E. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 133:2000;933-941.
38. Simon J.A., Hsia J., Cauley J.A., Richards C., Harris F., Fong J., et al. Postmenopausal hormone therapy and risk of stroke The Heart and Estrogen-Progestin Replacement Study (HERS) . Circulation. 103:2001;638-642.
39. Wassertheil-Smoller S., Hendrix S.L., Limacher M., Heiss G., Kooperberg C., Baird A., et al. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative a randomized trial . JAMA. 289:2003;2673-2684.
40. Viscoli C.M., Brass L.M., Kernan W.N., Sarrel P.M., Suissa S., Horwitz R.I. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 345:2001;1243-1249.
41. Miller J., Chan B.K.S., Nelson H.D. Postmenopausal estrogen replacement and risk for venous thromboembolism a systematic review and meta-analysis for the U.S. Preventive Services Task Force . Ann Intern Med. 136:2002;680-690.
42. Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 348:1996;977-980.
43. Devor M., Barrett-Connor E., Renvald M., Feigal D., Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med. 92:1992;275-282.
44. Grodstein F., Stampfer M.J., Goldhaber S.Z., Manson J.E., Colditz G.A., Speizer F.E., et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 348:1996;983-987.
45. Gutthann S.P., Garcia Rodriguez L.A., Castellsague J., Oliart A.D. Hormone replacement therapy and risk of venous thromboembolism population based case control study . Br Med J. 314:1997;796-800.
46. Jick H., Derby L.E., Wald Myers M., Vasilakis C., Newton K.M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 348:1996;981-983.
47. Hulley S., Furberg C., Barrett-Connor E., Cauley J., Grady D., Haskell W., et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy Heart and Estrogen/Progestin Replacement Study follow-up (HERS II) . JAMA. 288:2002;58-66.
48. Collins J.A., Schlesselman J.J. Hormone replacement therapy and endometrial cancer. Lobo R.A. Treatment of the postmenopausal woman. 1999;503-512 Lippincott Williams and Wilkins, Philadelphia.
49. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
50. Ross R.K., Paganini-Hill A., Wan P.C., Pike M.C. Effect of hormone replacement therapy on breast cancer risk estrogen versus estrogen plus progestin . J Natl Cancer Inst. 92:2000;328-332.
51. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L.A., Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 283:2000;485-491.
52. Colditz G.A., Hankinson S.E., Hunter D.J., Willett W.C., Manson J.E., Stampfer M.J., et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 332:1995;1589-1593.
53. Weiss L.K., Burkman R.T., Cushing-Haugen K.L., Voigt L.F., Simon M.S., Daling J.R., et al. Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol. 100:2002;1148-1158.
54. Sellers T.A., Mink P.J., Cerhan J.R., Zheng W., Anderson K.E., Kushi L.H., et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history for breast cancer. Ann Intern Med. 127:1997;973-980.
55. Schairer C., Gail M., Byrne C., Rosenberg P.S., Sturgeon S.R., Brinton L.A., et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst. 91:1999;264-270.
56. Nanda K., Bastian L.A., Hasselblad V., Simel D.L. Hormone replacement therapy and the risk of colorectal cancer a meta-analysis . Obstet Gynecol. 93:1999;880-888.
57. Grodstein F., Newcomb P.A., Stampfer M.J. Postmenopausal hormone therapy and the risk of colorectal cancer a review and meta-analysis . Am J Med. 106:1999;574-582.
58. Cramer D.W., Hutchison G.B., Welch W.R., Scully R.E., Ryan K.J. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst. 71:1983;711-716.
59. Hildreth N.G., Kelsey J.L., LiVolsi V.A., Fischer D.B., Holford T.R., Mostow E.D., et al. An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol. 114:1981;398-405.
60. Haas G.G., Cunningham M.E. Identification of antibody-laden sperm by cytofluorometry. Fertil Steril. 42:1984;606-613.
61. Coughlin S.S., Giustozzi A., Smith S.J., Lee N.C. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol. 53:2000;367-375.
62. Riman T., Dickman P.W., Nilsson S., Correia N., Nordlinder H., Magnusson C.M., et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst. 94:2002;497-504.
63. Lacey J.V. Jr, Mink P.J., Lubin J.H., Sherman M.E., Troisi R., Hartge P., et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 288:2002;334-341.
64. Rodriguez C., Patel A.V., Calle E.E., Jacob E.J., Thun M.J. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA. 285:2001;1460-1465.
65. Ryan P.J., Harrison R., Blake G.M., Fogelman I. Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol. 99:1992;325-328.
66. Archer D.F., Pickar J.H. Hormone replacement therapy effect of progestin dose and time since menopause on endometrial bleeding . Obstet Gynecol. 96:2000;899-905.
67. Archer D.F., Pickar J.H., Bottliglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol. 83:1994;686-692.
68. Pilon D., Castilloux A.-M., Lelorier J. Estrogen replacement therapy determinants of persistence with treatment . Obstet Gynecol. 97:2001;97-100.
69. Hodis H.N., Mack W.J., Azen S.P., Lobo R.A., Shoupe D., Mahrer P.R., et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 349:2003;535-545.
70. Manson J.E., Hsia J., Johnson K.C., Rossouw J.E., Assaf A.R., Lasser N.L., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 349:2003;523-534.
71. Nelson H.D., Humphrey L.L., Nygren P., Teutsch S.M., Allan J.D. Postmenopausal hormone replacement therapy scientific review . JAMA. 288:2002;872-881.
72. Scarabin P.Y., Oger E., Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism. Lancet. 362:2003;428-432.
73. Li C.I., Malone K.E., Porter P.L., Weiss N.S., Tang M.T., Cushing-Haugen K.L., et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 289:2003;3254-3263.
74. Chlebowski R.T., Hendrix S.L., Langer R.D., Stefanick M.L., Gass M., Lane D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women The Women's Health Initiative Randomized Trial . JAMA. 289:2003;3243-3253.
75. Beral V and the Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.